[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 456,097,600
  • Shares Outstanding, K 1,766,793
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 16,870 M
  • EBITDA $ 25,856 M
  • 60-Month Beta 0.30
  • Price/Sales 7.59
  • Price/Cash Flow 17.36
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 25.47% (+0.44%)
  • Historical Volatility 23.06%
  • IV Percentile 28%
  • IV Rank 39.69%
  • IV High 35.30% on 04/27/26
  • IV Low 19.01% on 08/29/25
  • Expected Move (DTE 6) 5.61 (2.20%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 16,415
  • Volume Avg (30-Day) 17,134
  • Put/Call OI Ratio 0.78
  • Today's Open Interest 265,730
  • Open Int (30-Day) 283,786
  • Expected Range 249.87 to 261.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $3.86
  • Number of Estimates 6
  • High Estimate $3.95
  • Low Estimate $3.77
  • Prior Year $1.86
  • Growth Rate Est. (year over year) +107.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
241.20 +5.92%
on 08/06/26
267.47 -4.48%
on 07/29/26
-7.72 (-2.93%)
since 07/28/26
3-Month
208.99 +22.25%
on 06/02/26
267.47 -4.48%
on 07/29/26
+36.85 (+16.85%)
since 05/28/26
52-Week
190.75 +33.93%
on 04/29/26
267.47 -4.48%
on 07/29/26
+47.56 (+22.87%)
since 08/28/25

Most Recent Stories

More News
AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

NORTH CHICAGO, Ill. , Aug. 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for SKYRIZI ...

ABBV : 255.48 (-1.03%)
2 S&P 500 Stocks with Exciting Potential and 1 We Brush Off

2 S&P 500 Stocks with Exciting Potential and 1 We Brush Off

TSLA : 348.75 (-1.71%)
ABBV : 255.48 (-1.03%)
DELL : 456.24 (-3.39%)
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

NORTH CHICAGO, Ill. , Aug. 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World...

ABBV : 255.48 (-1.03%)
3 Unpopular Stocks That Deserve Some Love

3 Unpopular Stocks That Deserve Some Love

CVX : 201.86 (+1.05%)
ABBV : 255.48 (-1.03%)
PLTR : 186.29 (+0.19%)
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

NORTH CHICAGO, Ill. , Aug. 18, 2026 /PRNewswire/ --  AbbVie (NYSE: ABBV) today announced 34 students living with inflammatory conditions across dermatology, gastroenterology and rheumatology...

ABBV : 255.48 (-1.03%)
2 Reasons to Like ABBV and 1 to Stay Skeptical

2 Reasons to Like ABBV and 1 to Stay Skeptical

ABBV : 255.48 (-1.03%)
Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

IRVINE, Calif. , Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced updates to Allergan Partner Privileges ® (APP), its customer portfolio loyalty program,...

ABBV : 255.48 (-1.03%)
MarketBeat Week in Review – 08/03 - 08/07

A weekly roundup of MarketBeat analysis covering earnings from AbbVie, AMD, Palantir, Meta, Reddit, SpaceX and others, plus upcoming CPI and PPI inflation data.

META : 578.02 (+1.21%)
ULTA : 517.50 (-4.18%)
SNDK : 1,484.98 (unch)
RDDT : 153.00 (-0.62%)
RKLB : 64.39 (-4.65%)
ADM : 81.54 (+3.08%)
ABBV : 255.48 (-1.03%)
INBK : 28.01 (+2.08%)
BOOT : 154.85 (-0.49%)
MCD : 265.00 (+1.90%)
SPCX : 141.50 (+0.45%)
AMD : 465.58 (-2.33%)
The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

ABBV : 255.48 (-1.03%)
3 Cash-Producing Stocks for Long-Term Investors

3 Cash-Producing Stocks for Long-Term Investors

CPAY : 407.88 (+1.04%)
ABBV : 255.48 (-1.03%)
CRGY : 13.54 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 261.88
2nd Resistance Point 260.44
1st Resistance Point 257.96
Last Price 255.48
1st Support Level 254.04
2nd Support Level 252.60
3rd Support Level 250.12

See More

52-Week High 267.47
Last Price 255.48
Fibonacci 61.8% 238.16
Fibonacci 50% 229.11
Fibonacci 38.2% 220.06
52-Week Low 190.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.